AI-based Measurements of Tumour Burden in PSMA PET-CT

Launched by ELIN TRAGARDH · Apr 9, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how an artificial intelligence (AI) program can help measure the amount of cancer in patients with prostate cancer using a special imaging test called a PSMA PET-CT scan. The researchers want to see if these AI-based measurements, which look at the size of the tumors and how much they take up certain substances in the body, can predict how long patients are likely to live after their diagnosis. This study is open to men who are 20 years and older and are scheduled for a PSMA PET-CT scan at Skåne University Hospital in Sweden.

If you or a loved one are diagnosed with prostate cancer and meet the eligibility criteria, you could be part of this important research. Participants will have their PSMA PET-CT scan as usual, and the AI will analyze the results to provide additional information about their cancer. This trial is currently recruiting, so it's a great opportunity for those looking to contribute to advancements in prostate cancer treatment and understanding.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden
• Exclusion Criteria:
• • Patients under 20 years old